UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

March 27, 2015

Date of Report (Date of earliest event reported)

Discovery Laboratories, Inc.
(Exact name of registrant as specified in its charter)

Delaware
000-26422
94-3171943
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)

2600 Kelly Road, Suite 100
Warrington, Pennsylvania 18976
(Address of principal executive offices)

(215) 488-9300
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


Item 5.02(e).  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 27, 2015 (the "Grant Date"), upon recommendation of the Compensation Committee of the Board of Directors of Discovery Laboratories, Inc. (the “Company”), the Board of Directors (the “Board”) of the Company approved stock option grants to two Named Executive Officers – John G. Cooper, President and Chief Executive Officer, and Mary B. Templeton, Esq., Senior Vice President, General Counsel & Corporate Secretary.  Mr. Cooper was granted 350,000 stock options at an exercise price of $1.17.  Ms. Templeton was granted 75,000 stock options at an exercise price of $1.17.  The options granted to Mr. Cooper and Ms. Templeton vest in three equal annual installments on the first, second and third anniversary of the Grant Date.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Discovery Laboratories, Inc.
 
       
 
By
/s/ John G. Cooper
 
 
Name: 
John G. Cooper
 
 
Title:
President and Chief Executive Officer
 

Date:  March 31, 2015